These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31232925)

  • 1. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.
    Mealy MA; Levy M
    Medicine (Baltimore); 2019 Jun; 98(25):e15944. PubMed ID: 31232925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks.
    Wang Y; Zhong X; Wang H; Peng Y; Shi F; Jia D; Yang H; Zeng Q; Quan C; ZhangBao J; Lee M; Qi J; Chen X; Qiu W;
    Eur J Neurol; 2023 Jan; 30(1):195-203. PubMed ID: 36087008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica.
    Levy M; Mealy MA
    Neurol Neuroimmunol Neuroinflamm; 2014 Jun; 1(1):e5. PubMed ID: 25340061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
    Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
    Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Dai Y; Ni S; Wu F; Guo S; Zhao X; Wang J
    J Clin Pharm Ther; 2022 Sep; 47(9):1379-1387. PubMed ID: 35488449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report.
    Huang SQ; Yuan ZH; Hong Y; Jiang T; Zhao HD; Shi JQ
    Neurol Sci; 2024 Nov; 45(11):5511-5515. PubMed ID: 38969961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
    Du C; Zeng P; Han JR; Zhang TX; Jia D; Shi FD; Zhang C
    Front Immunol; 2021; 12():660230. PubMed ID: 34745082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.
    Songthammawat T; Srisupa-Olan T; Siritho S; Kittisares K; Jitprapaikulsan J; Sathukitchai C; Prayoonwiwat N
    Mult Scler Relat Disord; 2020 Feb; 38():101506. PubMed ID: 31731214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India.
    James J; Gafoor VA; Jose J; Smita B; Balaram N
    J Neurosci Rural Pract; 2023; 14(2):327-332. PubMed ID: 37181182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.